Zytiga
Zytiga is the brand name for the drug abiraterone acetate. It is a medication used to treat a specific type of prostate cancer, known as castration-resistant prostate cancer (CRPC). This type of cancer continues to grow even when the body's testosterone levels are lowered through medical or surgical treatments. Zytiga is typically prescribed to men whose prostate cancer has spread to other parts of the body or who have not responded to chemotherapy.
Abiraterone acetate works by inhibiting an enzyme called CYP17A1. This enzyme is involved in the production
Zytiga is taken orally, usually once a day. It is generally administered along with a corticosteroid, such